Pharming Turns A Profit After Reclaiming Ruconest
Executive Summary
Pharming Group, a company that has been on the drug development scene since the ‘80s, has recorded a quarterly net profit for the first time – two years earlier than previously forecast.
You may also be interested in...
Profitable Pharming Expands Ruconest Potential And Resurrects Pompe Pipeline
Dutch rare disease company Pharming talked to Scrip about turning a profit for the first time in the company’s history, finally restocking the pipeline in potentially blockbuster indications, and turning its attention back to Pompe disease after 20 years in the cold.
VC View: Deal-Making During A Pandemic And 2021 Expectations
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Snapshot: August Highlights
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Need a specific report? 1000+ reports available
Buy Reports